The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: Single-institution results from a large cohort study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4390-4398

  Elisei, Rossella ^a   Viola, David ^a   Torregrossa, Liborio ^a   Giannini, Riccardo ^a   Romei, Cristina ^a   Ugolini, Clara ^a   Molinaro, Eleonora ^a   Agate, Laura ^a   Biagini, Agnese ^a   Lupi, Cristiana ^a   Valerio, Laura ^a   Materazzi, Gabriele ^a   Miccoli, Paolo ^a   Piaggi, Paolo ^a   Pinchera, Aldo ^a   Vitti, Paolo ^a   Basolo, Fulvio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; IODINE 131;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAF GENE; CANCER INFILTRATION; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; INTRATHYROID PAPILLARY THYROID CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CARCINOMA; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SAMPLE SIZE; THYROID GLAND; THYROID NEOPLASMS; VALINE; YOUNG ADULT;

EID: 84870726465     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1775     Document Type: Article

References (34)

1. Braverman LE, Utiger RD, eds. 2000 Werner and Ingbar's the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams, Wilkins
2. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167
3. Harach HR, Franssila KO, Wasenius VM 1985 Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56:531-538 (Pubitemid 15035581)
4. Elisei R, Molinaro E, Agate L, Bottici V, Masserini L, Ceccarelli C, Lippi F, Grasso L, Basolo F, Bevilacqua G, Miccoli P, Di Coscio G, Vitti P, Pacini F, Pinchera A 2010 Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 95:1516-1527
5. Leenhardt L, Grosclaude P, Chérié-Challine L 2004 Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060 (Pubitemid 40076130)
6. Nikiforova MN, Nikiforov YE 2008 Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 8:83-95
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457 (Pubitemid 36373628)
8. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397 (Pubitemid 37153748)
9. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404 (Pubitemid 37452745)
10. Lee JH, Lee ES, Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46
11. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762 (Pubitemid 350294294)
12. Lin KL, Wang OC, Zhang XH, Dai XX, Hu XQ, Qu JM 2010 The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol 17:3294-3300
13. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379 (Pubitemid 41759286)
14. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364-368
15. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
16. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 2010 AJCC cancer staging manual. 7th ed. New York: Springer
17. Cooper DS, Doherty GM, Haugen BR, Hauger BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
18. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803 (Pubitemid 43997716)
19. DeLellis RA 2004 Thyroid and parathyroid tumors. In: DeLellis RA, ed. Pathology and genetics tumours of endocrine organs. Lyon, France: IARC Press
20. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK eds. 2011 SEER Cancer Statistics Review, 1975-2008. http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site. Bethesda, MD: National Cancer Institute
21. Pellegriti G, Scollo C, Lumera G, Regalbuto C, Vigneri R, Belfiore A 2004 Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 89:3713-3720 (Pubitemid 39071462)
22. Roti E, degli Uberti EC, Bondanelli M, Braverman LE 2008 Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 159:659-673
23. Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R 2009 BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27:2977-2982
24. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
25. Basolo F, Torregrossa L, Giannini R, Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A, Miccoli P 2010 Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 95:4197-4205
26. Ugolini C, Giannini R, Lupi C, Salvatore G, Miccoli P, Proietti A, Elisei R, Santoro M, Basolo F 2007 Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 17:381-388 (Pubitemid 46878840)
27. Sipos JA, Mazzaferri EL 2010 Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22:395-404
28. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, Zhang Y, Shan Z, Teng W, Xing M 2009 Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 94:1612-1617
29. Rivera M, Tuttle RM, Patel S, Shaha A, Shah JP, Ghossein RA 2009 Encapsulated papillary thyroid carcinoma: a clinico-pathologic study of 106 cases with emphasis on its morphologic subtypes (histologic growth pattern). Thyroid 19:119-127
30. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, Singh B, Ghossein RA 2006 Poorly differentiated thyroid carci- nomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer 106:1286-1295 (Pubitemid 43363905)
31. Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA 2010 Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol 23:1191-1200
32. Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R 2008 BRAF V600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer 15:511-520 (Pubitemid 351880839)
33. Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P 2006 The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13:257-269
34. Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, Opocher G, Busnardo B, Girelli ME 2008 Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 68:108-116 (Pubitemid 350243490)